EXACT Sciences — Q2 2024 Earnings Presentation
20 slides from EXACT Sciences's earnings presentation, Jul 31, 2024
Slide 1: Second-quarter 2024 earnings call
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Second-quarter 2024 earnings call July 31, 2024 EXACT SCIENCES 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Exact Sciences is a leader in advanced cancer diagnostics
Exact Sciences is a leader in advanced cancer diagnostics OUR TEAM OUR FLAGSHIP TESTS Q2 RESULTS 500 1M+ Record total revenue of $699M, 13% core revenue growth R&D team members test results in 2Q24 1,350 Record adj. EBITDA of $110M, or 16% margin rate, and free cash flow of $71M person commercial te
Slide 4: Core revenue grew 13% in 2Q24
Core revenue grew 13% in 2Q24 Core revenue Screening revenue Precision Oncology core revenue $696M $618M +13% $532M $463M +15% $155M $164M +6% 2Q23 2Q24 2Q23 2Q24 2Q23 2Q24 Please refer to our second-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP financial measures and
Slide 5: Delivered record profitability and strengthened our balance sheet
Delivered record profitability and strengthened our balance sheet Adjusted EBITDA Free cash flow Adjusted EBITDA margin $110M 15.7% +$43M +500 bps $71M $67M $66M +$5M 10.7% 2Q23 2Q24 2Q23 2Q24 Please refer to our second-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP fi
Slide 6: Maintaining full-year revenue guidance and raising full-year adjusted EBITDA guidance
Maintaining full-year revenue guidance and raising full-year adjusted EBITDA guidance Prior guidance July 31 update ∆ at midpoint Total revenue $2.810 - 2.850B $2.810 - 2.850B - Screening $2.155 - 2.175B $2.155 - 2.175B - Precision Oncology $655 - 675M $655 - 675M - Adj. EBITDA $325 - 350M $335 - 35
Slide 7: Cologuard revolutionized colorectal cancer screening and momentum continues to build
Cologuard revolutionized colorectal cancer screening and momentum continues to build 1M+ Colorectal cancer screening rates U.S. screening eligible population age 50-75 +13 pts. people screened in Q2 2024 20M launch rescreen opportunities with Cologuard patients ages 45-49 100+ care gap program oppor
Slide 8: Key Cologuard growth drivers
Key Cologuard growth drivers Increasing Cologuard utilization among primary care clinicians Partnering with health systems to address unscreened patients Helping payers improve screening rates and quality metrics Ensuring people remain screened with Cologuard every 3 years Getting 19M unscreened Ame
Slide 9: Using our oncology foundation to increase genomic testing around the world
Using our oncology foundation to increase genomic testing around the world international adoption 200K+ international patients eligible for Oncotype DX every year ~10%+ +10 pts. 25% increase in international ~30% ordering providers y/y ~20% ASCO® ST. GALLEN NCCN® ESMO NICE included in all major guid
Slide 10: Progress in key pipeline programs with several milestones upcoming
Progress in key pipeline programs with several milestones upcoming Colon cancer Molecular residual Multi-cancer screening disease screening Generated data supporting Generated colon cancer Authorized by FDA for use in blood-based test validation data 25K person real-world study Expecting Cologuard P
Slide 11: Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment EXACT SCIENCES 11
Slide 12: EXACT SCIENCES
EXACT SCIENCES 12
Slide 13: Condensed Consolidated Statements of Operations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenue $ 699,264 $ 622,093 $ 1,336,788 $ 1,224,543 Operating ex
Slide 14: Condensed Consolidated Balance Sheets
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) December 31, June 30, 2024 2023 Assets Cash and cash equivalents $ 530,180 $ 605,378 Marketable securities 416,602 172,266 Accounts receivable, net 263,865 203,623 Invento
Slide 15: Reconciliation of Core Revenue
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended June 30, 2024 2023 % Change Screening $ 531,606 $ 462,787 15 % Precision Oncology 167,658 157,174 7 % COVID-19 Testing — 2,132 (100) % Total $ 699,264 $ 6
Slide 16: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenue $ 699,264 $ 622,093 $ 1,336,788 $ 1,224,543 Cost of sales (excl
Slide 17: EBITDA and Adjusted EBITDA Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss $ (15,808) $ (81,026) $ (126,036) $ (155,177) Interest expense (income) (1) (111) 7
Slide 18: Reconciliation of U.S. GAAP to Non-GAAP Measures
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended June 30, 2024 Research & General & Amortization of Development Sales & Marketing Administrative acquired intangiible Impairment of Other Oper
Slide 19: Reconciliation of U.S. GAAP to Non-GAAP Measures
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended June 30, 2023 Research & General & Amortization of Development Sales & Marketing Administrative acquired intangiible Impairment of Other Oper
Slide 20: Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net cash provided by operating activities 107,065